Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

Register

Sign In

EUR/USD

1.1751

-0.0041

-0.35%

GBP/USD

1.3187

-0.0058

-0.44%

USD/JPY

112.37

0.2025

0.18%

USD/CHF

0.9792

0.0036

0.37%

EUR/GBP

0.8911

0.0008

0.09%

USD/CAD

1.2539

0.0019

0.15%

NZD/USD

0.7165

-0.0021

-0.29%

EUR/JPY

132.05

-0.2245

-0.17%

EUR/CHF

1.1507

0.0003

0.03%

Ardelyx Inc

NASDAQ: ARDXHealthcare / Biotechnology / USA
6.40-0.88-12.09%Vol 2 408 2941Y Perf -50.12%
Oct 16th, 2017 16:00
BID6.40 ASK6.60
Open7.35 Previous Close7.28
Pre-Market6.70 After-Trading6.40
 0.30 4.69%  - -%
Target Price
16.33 
Analyst Rating
Strong Buy 1.00
Potencial %
155.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-100/-100/-100 
Income Ranking
 —    -
Market Cap (mil)304 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
19.18 
Earnings Date
6th Nov 2017

Today's Price Range

6.257.50

 

52wk Range

4.0516.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
20.75%
3 Months
11.30%
6 Months
-46.67%
1 Year
-50.12%
3 Years
-69.19%
5 Years
-
Last Quotes
Name / TickerPriceChg.Chg.%
ARDX6.40-0.8800-12.09
AAPL159.882.89001.84
GOOG992.002.32000.23
MSFT77.650.16000.21
XOM82.810.40000.49
WFC53.800.11000.20
JNJ136.12-0.3100-0.23
FB174.520.78000.45
GE23.360.38001.65
JPM97.841.98002.07
...

TickerPriceChg.%52 Week High
DVA56.934.0270.16
FCX15.273.5317.06
WYNN146.813.15150.40
NBL27.902.7642.03
APA42.732.7269.00
MU41.492.7042.07
HES46.042.3365.56
DFS65.352.3074.33
SYF31.502.2138.06
NRG26.622.1526.68
JPM97.842.0797.95
AMAT55.042.0455.09
BWA52.172.0352.71
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 8.10
Current Ratio 8.40
Long Term Debt to Total Capital -
Total Debt to Equity -
Interest Coverage -
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin-
EBIT Margin-
EBITDA Margin-
Pre-tax Profit Margin-
Profit Margin-
ValuationValueIndustryS&P 500US Markets
PE Ratio -
PB Ratio 2.38
PS Ratios -
Price to Cash Flow 58.30
Price to Free Cash Flow -4.20
Cash Flow Per Share -2.19
Price to Tangible Book2.38
Book Value per Share3.06
Enterprise Value (in ths.)196 439
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-59.90
ROE last 12 Months -78.75
Return on Assets (5Y Avg) -20.65
ROA last 12 Months -70.40
Return on Capital (5Y Avg) -
ROC last 12 Months -79.86
Return on invested Capital Q -16.45
Return on invested Capital Y-74.42
Assets Turnover0.00
Receivables Turnover0.00
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)0
Revenue per Share 0.00
Revenue Growth 3 Years -
Revenue Growth 5 Years -
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q02 2017-0.63-0.5414.29
Q01 2017-0.65-0.599.23
Q04 2016-0.63-0.66-4.76
Q03 2016-0.70-0.657.14
Q02 2016-0.67-0.83-23.88
Q01 2016-0.65-0.70-7.69
Q04 2015-0.74-0.6512.16
Q03 2015-0.36-0.70-94.44
Earnings Per EndEstimateRevision %Trend
9/2017 QR-0.5615.15Positive
12/2017 QR-0.5028.57Positive
12/2017 FY-2.1815.50Positive
12/2018 FY-2.44-11.93Negative
Next Report Date6th Nov 2017
Estimated EPS Next Report-0.56
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume2 408 294
Shares Outstanding (in ths.)47 440
Trades Count6 934
Dollar Volume15 558 824
Avg. Volume482 446
Avg. Weekly Volume6 947 971
Avg. Monthly Volume1 910 268
Avg. Quarterly Volume773 873

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

58%42%

Bearish Bullish

57%43%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

There are no comments yet.

News

x